All News

pregnancy,birth,preterm,baby

Autoimmune disease and pregnancy

EurekAlert!

 For many aspiring mothers with autoimmune disease, pregnancy can be daunting and full of unknowns. In some cases, those suffering from specific autoimmune conditions have chosen to forego pregnancy altogether due to concerns about their disease treatments and adverse pregnancy outcomes.

Read Article
Rheumatoid,RA,nodules,damage

SeXXist Reason for More Women with Autoimmune Disease

EurekAlert!

Somewhere between 24 and 50 million Americans have an autoimmune disease, a condition in which the immune system attacks our own tissues. As many as 4 out of 5 of those people are women.

Read Article
RheumNow Podcast square

Methotrexate Nodulosis (1.19.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com. How good (or not) are rheumatologists and what to do about MTX nodulosis?

Read Article
myositis.jpg

Increased CV Comorbidity in Dermatomyositis

Jack Cush, MD

A cohort study suggest that patients with dermatomyositis (DM) are at an increased risk for multiple comorbidities, including chronic kidney and cardiovascular disease,

Read Article
Jo1.gottrons.jpg

Drug-Induced Dermatomyositis

Jack Cush, MD

A JAMA Dermatology systematic review of drug-induced dermatomyositis (DM) found the most commonly implicated agents include hydroxyurea, immune checkpoint inhibitors, statins and lipid-lowering agents, penicillamine, and tumor necrosis factor inhibitors.

Read Article
RheumNow Podcast square

RheumNow Podcast – Bill of Rights (12.15.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Two major reports on fatigue and fibromyalgia misfired, and "ankylosing spondylitis" is sent to the Rheumatology dead word cemetery. 

Read Article
RheumNow Podcast square

Sleep Apnea Smart Watches (10.13.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal reports and regulatory approvals from this past week on RheumNow.com.

Read Article
RheumNow Podcast square

Hard Decisions in RA (9.1.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow, and introduces our September campaign - "Hard Decisions in RA".

Read Article
Cancer and Myositis #RNL2024 @RheumNow @DrLisaCS on Cancer screening: Risk stratify: dermatomyositis, NXP2, TIFy, <40yo, refractory, dysphagia, cutaneous necrosis at higher risk Enhanced risk stratification for those at risks, versus "basic screening" for lower risks https://t.co/3yy9Fx1pk8

Links:

Eric Dein ericdeinmd ( View Tweet)
Dr Christopher-Stine @DrLisaCS Factors which should influence (some very strongly) your cancer screening approach in myositis @RheumNow #RNL2024 https://t.co/BoyJLrVDwo

Links:

Richard Conway RichardPAConway ( View Tweet)
anti-Sp4 Ab may be protective against cancer in myositis pts who are TIF1-g positive - Dr. L Christopher-Stine #RNL2024 @rheumnow https://t.co/n7Ikn3llGH

Links:

TheDaoIndex KDAO2011 ( View Tweet)
Continue to love this myositis diagram. Seems to be getting ever more complicated though! @DrLisaCS @RheumNow #RNL2024 https://t.co/eXz6144y3y

Links:

Richard Conway RichardPAConway ( View Tweet)
Cancer and Myositis #RNL2024 @RheumNow @DrLisaCS Dermatomyositis risks - TIF1y is highest risk, followed by NXP2 Protective features: childhood onset, ILD, arthralgias Cancer and myositis often present w/in 1 yr before or after Cancer is major cause of death

Eric Dein ericdeinmd ( View Tweet)

Increased CV Comorbidity in Dermatomyositis A cohort study suggest that patients with dermatomyositis (DM) are at an increased risk for multiple comorbidities, including chronic kidney and cardiovascular disease, https://t.co/bYvd5AhqSl https://t.co/4y4kjYhTm3

Links:

Dr. John Cush RheumNow ( View Tweet)
JAMA: cutaneous hallmarks of dermatomyositis. Printable Patient education overview. https://t.co/S7MaAz6fX2 https://t.co/5ETcQRz8Fd

Links:

Dr. John Cush RheumNow ( View Tweet)
Programmed-cell-death 1 (PD-1) expression on T-cells is assoc w/ activation & exhaustion. The exhausted phenotype of PD-1+CD8+ T cells add to the pathogenesis of active idiopathic inflammatory myositis. https://t.co/xOYfEs16ou https://t.co/MzEPpUc7Eb

Links:

Dr. John Cush RheumNow ( View Tweet)
Thanks #ACR23 for a wonderful meeting ! Presented a really positive phase 2 clinical trial results of Dazukibart, an IFN beta monoclonal antibody in #Myositis (DM) #pfizer .Strong efficacy with rapid onset. Safe & tolerable monthly IV injection. Looking forward to start Phase 3. https://t.co/580ICHM8Hs
Rohit Aggarwal  ( View Tweet)
#ACR23 Abstr#2578 AI to phenotype sporadic IBM vs AI Myositis -Anti-NT5c1A assoc with dysphagia -Anti-Ro52/TRIM21: female -Anti-VCP: male -Anti-NT5c1A + clinical markers: high accuracy in separating SIBM vs AIM Need longitudinal data for clusters to be meaningful @RheumNow https://t.co/fu0a074XAZ
Md Yuzaiful Md Yusof  ( View Tweet)
#ACR23 Abstr#2580 Could high-intensity resistance training improve outcomes in myositis? RCT showed 16 wks of training was tolerable, improved quality of life & functional capacity, without increasing disease activity/damage @RheumNow https://t.co/O1nP2x9C1L
Md Yuzaiful Md Yusof  ( View Tweet)
Don’t forget: 👉anti-HMGCR Ab in patients with immune mediated necrotizing myositis (may be assc with statins) 👉Anti-synthetase Ab assc with ILD, anti-synthetase syndrome #Rheum #BoardQuestion https://t.co/pBAADeR9ON

TheDaoIndex KDAO2011 ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×